{"id":61946,"date":"2026-03-31T14:27:17","date_gmt":"2026-03-31T06:27:17","guid":{"rendered":"https:\/\/flcube.com\/?p=61946"},"modified":"2026-03-31T14:27:18","modified_gmt":"2026-03-31T06:27:18","slug":"dizal-pharmaceutical-reports-record-sales-growth-driven-by-nrdl-inclusion-of-sunvozertinib-and-golidocitinib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61946","title":{"rendered":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib"},"content":{"rendered":"\n<p><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) reported exceptional commercial performance in its 2025 financial results, with <strong>sunvozertinib (Zegfrovy)<\/strong> generating <strong>RMB 576 million<\/strong> (USD 83.4 million) in revenue following an <strong>85.21% year-over-year expansion<\/strong>. The company&#8217;s total sales reached <strong>RMB 801 million<\/strong> (USD 116 million), marking a <strong>122.60% YOY increase<\/strong>, driven primarily by the inclusion of both commercialized products in China&#8217;s <strong>National Reimbursement Drug List (NRDL)<\/strong> for the first time in 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2025 Result<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Sales Revenue<\/strong><\/td><td>RMB 801M (USD 116M)<\/td><td>+122.60%<\/td><\/tr><tr><td><strong>Sunvozertinib Revenue<\/strong><\/td><td>RMB 576M (USD 83.4M)<\/td><td>+85.21%<\/td><\/tr><tr><td><strong>Golidocitinib Revenue<\/strong><\/td><td>RMB 226M (USD 32.7M)<\/td><td>+359.32%<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>RMB 856M (USD 124M)<\/td><td>+18.23%<\/td><\/tr><tr><td><strong>Net Loss<\/strong><\/td><td>RMB 764M (USD 111M)<\/td><td>N\/A<\/td><\/tr><tr><td><strong>Cash &amp; Cash Equivalents<\/strong><\/td><td>RMB 1.936B (USD 280M)<\/td><td>+130.5% vs. 2024<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-portfolio-highlights\">Product Portfolio Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-sunvozertinib-zegfrovy\">Sunvozertinib (Zegfrovy)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Next-generation EGFR inhibitor for <strong>EGFR Exon20ins mutated non-small cell lung cancer<\/strong><\/li>\n\n\n\n<li><strong>China Approval:<\/strong> August 2023<\/li>\n\n\n\n<li><strong>US FDA Approval:<\/strong> July 2025<\/li>\n\n\n\n<li><strong>NRDL Inclusion:<\/strong> 2025 (first-time)<\/li>\n\n\n\n<li><strong>Commercial Impact:<\/strong> Positioned for global market expansion following US regulatory milestone<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-golidocitinib\">Golidocitinib<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> World&#8217;s first and only novel mechanism drug targeting the <strong>JAK\/STAT pathway for PTCL<\/strong> (Peripheral T-cell Lymphoma)<\/li>\n\n\n\n<li><strong>NRDL Inclusion:<\/strong> 2025 (first-time)<\/li>\n\n\n\n<li><strong>Commercial Impact:<\/strong> Exceptional 359.32% YOY growth demonstrates strong market demand for innovative oncology therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-pipeline-overview\">Strategic Pipeline Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Pipeline Assets:<\/strong> 7 products in development<\/li>\n\n\n\n<li><strong>Commercialized Products:<\/strong> 2 (sunvozertinib and golidocitinib)<\/li>\n\n\n\n<li><strong>NRDL Status:<\/strong> Both commercial products secured reimbursement coverage in 2025<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Sunvozertinib&#8217;s FDA approval opens US market opportunity<\/li>\n\n\n\n<li><strong>Financial Strength:<\/strong> Cash position more than doubled to RMB 1.936 billion, providing runway for continued R&amp;D investment<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-analysis-amp-outlook\">Market Analysis &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>NRDL Inclusion<\/strong><\/td><td>Immediate access to China&#8217;s 1.4 billion population through public insurance coverage<\/td><\/tr><tr><td><strong>FDA Approval<\/strong><\/td><td>Sunvozertinib becomes Dizal&#8217;s first globally approved product, enabling international partnerships<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>Sustained 18.23% increase demonstrates commitment to innovation despite net losses<\/td><\/tr><tr><td><strong>Cash Position<\/strong><\/td><td>Strong liquidity supports pipeline advancement and potential business development activities<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The company&#8217;s strategic focus on innovative oncology assets with novel mechanisms has yielded significant commercial success. The simultaneous NRDL inclusion of both products in 2025 created immediate market access, while sunvozertinib&#8217;s FDA approval positions Dizal as an emerging global player in precision oncology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-forward-guidance\">Forward Guidance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Trajectory:<\/strong> Expect continued strong growth in 2026 driven by full-year NRDL benefits and US market entry for sunvozertinib<\/li>\n\n\n\n<li><strong>Pipeline Advancement:<\/strong> Robust cash position supports advancement of remaining 5 pipeline assets<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Potential licensing partnerships for sunvozertinib in major international markets<\/li>\n\n\n\n<li><strong>Profitability Path:<\/strong> Operating leverage from growing revenue base may improve path to profitability despite continued R&amp;D investment<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Dizal Pharmaceutical&#8217;s financial performance, product commercialization, regulatory approvals, and business strategy. Actual results may differ materially due to regulatory, competitive, and market risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688192_20260331_HJPD.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688192_20260331_HJPD.\"><\/object><a id=\"wp-block-file--media-ba013384-7220-47f1-8479-df1545b23746\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688192_20260331_HJPD.pdf\">688192_20260331_HJPD<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/688192_20260331_HJPD.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ba013384-7220-47f1-8479-df1545b23746\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":61949,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[191,27,981],"class_list":["post-61946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-dizal-pharmaceutical","tag-finanical-reports","tag-sha-688192"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company&#039;s total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China&#039;s National Reimbursement Drug List (NRDL) for the first time in 2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=61946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company&#039;s total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China&#039;s National Reimbursement Drug List (NRDL) for the first time in 2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=61946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-31T06:27:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T06:27:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib\",\"datePublished\":\"2026-03-31T06:27:17+00:00\",\"dateModified\":\"2026-03-31T06:27:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946\"},\"wordCount\":455,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101.webp\",\"keywords\":[\"Dizal Pharmaceutical\",\"Finanical Reports\",\"SHA: 688192\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61946#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=61946\",\"name\":\"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101.webp\",\"datePublished\":\"2026-03-31T06:27:17+00:00\",\"dateModified\":\"2026-03-31T06:27:18+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company's total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China's National Reimbursement Drug List (NRDL) for the first time in 2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=61946\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/3101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=61946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company's total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China's National Reimbursement Drug List (NRDL) for the first time in 2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=61946","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company's total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China's National Reimbursement Drug List (NRDL) for the first time in 2025.","og_url":"https:\/\/flcube.com\/?p=61946","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-31T06:27:17+00:00","article_modified_time":"2026-03-31T06:27:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=61946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=61946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib","datePublished":"2026-03-31T06:27:17+00:00","dateModified":"2026-03-31T06:27:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=61946"},"wordCount":455,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=61946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","keywords":["Dizal Pharmaceutical","Finanical Reports","SHA: 688192"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=61946#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=61946","url":"https:\/\/flcube.com\/?p=61946","name":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=61946#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=61946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","datePublished":"2026-03-31T06:27:17+00:00","dateModified":"2026-03-31T06:27:18+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) reported exceptional commercial performance in its 2025 financial results, with sunvozertinib (Zegfrovy) generating RMB 576 million (USD 83.4 million) in revenue following an 85.21% year-over-year expansion. The company's total sales reached RMB 801 million (USD 116 million), marking a 122.60% YOY increase, driven primarily by the inclusion of both commercialized products in China's National Reimbursement Drug List (NRDL) for the first time in 2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=61946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=61946"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=61946#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","width":1080,"height":608,"caption":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=61946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Reports Record Sales Growth Driven by NRDL Inclusion of Sunvozertinib and Golidocitinib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/3101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=61946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61946\/revisions"}],"predecessor-version":[{"id":61951,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/61946\/revisions\/61951"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/61949"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=61946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=61946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=61946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}